Cargando…
English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia
BACKGROUND: the first quality of life questionnaire specific to sarcopenia, the SarQoL(®), has recently been developed and validated in French. To extend the availability and utilisation of this questionnaire, its translation and validation in other languages is necessary. OBJECTIVE: the purpose of...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396804/ https://www.ncbi.nlm.nih.gov/pubmed/27789428 http://dx.doi.org/10.1093/ageing/afw192 |
_version_ | 1783230145484554240 |
---|---|
author | Beaudart, Charlotte Edwards, Mark Moss, Charlotte Reginster, Jean-Yves Moon, Rebecca Parsons, Camille Demoulin, Christophe Rizzoli, René Biver, Emmanuel Dennison, Elaine Bruyere, Olivier Cooper, Cyrus |
author_facet | Beaudart, Charlotte Edwards, Mark Moss, Charlotte Reginster, Jean-Yves Moon, Rebecca Parsons, Camille Demoulin, Christophe Rizzoli, René Biver, Emmanuel Dennison, Elaine Bruyere, Olivier Cooper, Cyrus |
author_sort | Beaudart, Charlotte |
collection | PubMed |
description | BACKGROUND: the first quality of life questionnaire specific to sarcopenia, the SarQoL(®), has recently been developed and validated in French. To extend the availability and utilisation of this questionnaire, its translation and validation in other languages is necessary. OBJECTIVE: the purpose of this study was therefore to translate the SarQoL(®) into English and validate the psychometric properties of this new version. DESIGN: cross-sectional. SETTING: Hertfordshire, UK. SUBJECTS: in total, 404 participants of the Hertfordshire Cohort Study, UK. METHODS: the translation part was articulated in five stages: (i) two initial translations from French to English; (ii) synthesis of the two translations; (iii) backward translations; (iv) expert committee to compare the backward translations with the original questionnaire and (v) pre-test. To validate the English SarQoL(®), we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test–retest reliability) and floor/ceiling effects. RESULTS: the SarQoL(®) questionnaire was translated without any major difficulties. Results indicated a good discriminative power (lower score of quality of life for sarcopenic subjects, P = 0.01), high internal consistency (Cronbach’s alpha of 0.88), consistent construct validity (high correlations found with domains related to mobility, usual activities, vitality, physical function and low correlations with domains related to anxiety, self-care, mental health and social problems) and excellent test– retest reliability (intraclass coefficient correlation of 0.95, 95%CI 0.92–0.97). Moreover, no floor/ceiling has been found. CONCLUSIONS: a valid SarQoL(®) English questionnaire is now available and can be used with confidence to better assess the disease burden associated with sarcopenia. It could also be used as a treatment outcome indicator in research. |
format | Online Article Text |
id | pubmed-5396804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-53968042017-09-01 English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia Beaudart, Charlotte Edwards, Mark Moss, Charlotte Reginster, Jean-Yves Moon, Rebecca Parsons, Camille Demoulin, Christophe Rizzoli, René Biver, Emmanuel Dennison, Elaine Bruyere, Olivier Cooper, Cyrus Age Ageing Article BACKGROUND: the first quality of life questionnaire specific to sarcopenia, the SarQoL(®), has recently been developed and validated in French. To extend the availability and utilisation of this questionnaire, its translation and validation in other languages is necessary. OBJECTIVE: the purpose of this study was therefore to translate the SarQoL(®) into English and validate the psychometric properties of this new version. DESIGN: cross-sectional. SETTING: Hertfordshire, UK. SUBJECTS: in total, 404 participants of the Hertfordshire Cohort Study, UK. METHODS: the translation part was articulated in five stages: (i) two initial translations from French to English; (ii) synthesis of the two translations; (iii) backward translations; (iv) expert committee to compare the backward translations with the original questionnaire and (v) pre-test. To validate the English SarQoL(®), we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test–retest reliability) and floor/ceiling effects. RESULTS: the SarQoL(®) questionnaire was translated without any major difficulties. Results indicated a good discriminative power (lower score of quality of life for sarcopenic subjects, P = 0.01), high internal consistency (Cronbach’s alpha of 0.88), consistent construct validity (high correlations found with domains related to mobility, usual activities, vitality, physical function and low correlations with domains related to anxiety, self-care, mental health and social problems) and excellent test– retest reliability (intraclass coefficient correlation of 0.95, 95%CI 0.92–0.97). Moreover, no floor/ceiling has been found. CONCLUSIONS: a valid SarQoL(®) English questionnaire is now available and can be used with confidence to better assess the disease burden associated with sarcopenia. It could also be used as a treatment outcome indicator in research. 2017-03-01 /pmc/articles/PMC5396804/ /pubmed/27789428 http://dx.doi.org/10.1093/ageing/afw192 Text en http://creativecommons.org/licenses/by-nc/4.0// This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Article Beaudart, Charlotte Edwards, Mark Moss, Charlotte Reginster, Jean-Yves Moon, Rebecca Parsons, Camille Demoulin, Christophe Rizzoli, René Biver, Emmanuel Dennison, Elaine Bruyere, Olivier Cooper, Cyrus English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia |
title | English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia |
title_full | English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia |
title_fullStr | English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia |
title_full_unstemmed | English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia |
title_short | English translation and validation of the SarQoL(®), a quality of life questionnaire specific for sarcopenia |
title_sort | english translation and validation of the sarqol(®), a quality of life questionnaire specific for sarcopenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396804/ https://www.ncbi.nlm.nih.gov/pubmed/27789428 http://dx.doi.org/10.1093/ageing/afw192 |
work_keys_str_mv | AT beaudartcharlotte englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT edwardsmark englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT mosscharlotte englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT reginsterjeanyves englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT moonrebecca englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT parsonscamille englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT demoulinchristophe englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT rizzolirene englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT biveremmanuel englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT dennisonelaine englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT bruyereolivier englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia AT coopercyrus englishtranslationandvalidationofthesarqolaqualityoflifequestionnairespecificforsarcopenia |